Ocumension Therapeutics (1477 – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ziyi Chen from Goldman Sachs maintained a Buy rating on the stock and has a HK$6.93 price target.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Ziyi Chen has given his Buy rating due to a combination of factors that highlight Ocumension Therapeutics’ promising outlook. A key element in his assessment is the company’s confidence in their OT-101 (low dose atropine) program, which is currently under business development negotiations. The management has expressed optimism about the Phase 3 data for OT-101 in treating myopia in children and adolescents, with expectations for a data readout in May 2026. This study is designed to meet regulatory requirements in both the US and China, with a significant number of participants enrolled globally.
Another factor influencing the Buy rating is the anticipated resumption of Yutiq supply and the reiterated guidance for fiscal year 2025, which suggests a doubling of sales. The management’s strategic focus on securing out-licensing deals and navigating regulatory pathways in key markets further supports the positive outlook. Additionally, the recent approval of SYD-101 in the EU and the upcoming FDA PDUFA decision are seen as pivotal events that could enhance the company’s visibility and market penetration in the US. These elements collectively contribute to Ziyi Chen’s positive assessment of Ocumension Therapeutics’ stock.
Chen covers the Healthcare sector, focusing on stocks such as Innovent Biologics, Luye Pharma Group, and The United Laboratories International Holdings. According to TipRanks, Chen has an average return of -0.2% and a 39.66% success rate on recommended stocks.